The President & His Leadership Team The President's Management Agenda Tools for Success
  |   Messages From The President Video and transcripts of recent remarks.   |     |   Appointee Directory Get bios and photos of appointees online.   |     |   Department Links Links to departments and cabinet level offices.
Appointee Directory

Andrew von Eschenbach -- Department of Health and Human Services
Commissioner of the United States Food and Drug Administration

Andrew C. von Eschenbach, M.D., was sworn in as the 20th Commissioner of the U.S. Food and Drug Administration on December 13, 2006. As Commissioner, he leads the nation's premiere consumer protection and health agency, with regulated products that account for more than 20% of consumer spending. As the former Director of the National Cancer Institute (NCI), Dr. von Eschenbach is a nationally recognized urologic surgeon and oncologist. His distinguished career as a key leader in the fight against cancer spans nearly three decades. Prior to being appointed to lead the NCI in January 2002, Dr. von Eschenbach served as Executive Vice President and Chief Academic Officer of the University of Texas M.D. Anderson Cancer Center in Houston, leading a faculty of more than 1,000 cancer researchers and clinicians. At M.D. Anderson he also served as Vice President for Academic Affairs and held the Roy M. and Phyllis Gough Huffington Clinical Research Distinguished Chair in Urologic Oncology. Dr. von Eschenbach, as founding director of the Prostate Cancer Research Program, was instrumental in fostering integrated research programs in the biology, epidemiology, prevention, and treatment of prostate cancer at M.D. Anderson where he also directed the Genitourinary Cancer Center. He joined M.D. Anderson as a urologic oncology fellow in 1976 and was invited to join the faculty the following year. Just six years later - in 1983 - he was named chairman of the Department of Urology. Other positions held at M.D. Anderson include Consulting Professor of Cell Biology and Professor of Urology. Dr. von Eschenbach, himself a cancer survivor, has had an impact on the fight against cancer that extends beyond the clinical and academic communities. He is a founding member of C-Change and was president-elect of the American Cancer Society at the time of his appointment to the NCI. In addition, he has made significant contributions to the scientific literature -- more than 200 articles, books, and book chapters. Dr. von Eschenbach has also served as an editorial board member of several leading journals and on several organizational boards. Many influential organizations have recognized Dr. von Eschenbach for his leadership and accomplishments; among them the American Medical Writers Association, the American Urological Association, and the Uniformed Services University of Health Sciences. He also has been included in “The Best Doctors in America” publications. Included among his many honors are the 2003 Carpe Diem Award from the Lance Armstrong Foundation; the Achievement Award from the 100 Black Men of Metropolitan Houston for his significant contributions to prostate cancer programs in the African-American community, the Julie Rogers “Spirit of Love” Award for demonstrating unparalleled dedication, commitment, and spirit in the fight against cancer, and the American Radium Society Janeway Medal for outstanding contribution to cancer research and the care of cancer patients. In 2006, Time Magazine chose Dr. von Eschenbach as one of the 100 most influential people to shape the world. A native of Philadelphia, Dr. von Eschenbach earned a B.S. from St. Joseph’s University in Philadelphia in 1963 and his medical degree from Georgetown University School of Medicine in 1967. Dr. von Eschenbach completed internship at Philadelphia General Hospital and residency in urologic surgery at Pennsylvania Hospital in Philadelphia and then was an instructor in urology at the University of Pennsylvania School of Medicine. He also served as a Lieutenant Commander in the U.S. Navy Medical Corps.

Graphical Version | Privacy Statement